| NCT01641822 | Gilead Sciences | Cystic Fibrosis | 2012-12 | PHASE3 |
| NCT04678154 | Major Extremity Trauma Research Consortium|United States Department of Defense | Post Operative Surgical Site Infection | 2021-05-07 | PHASE3 |
| NCT04964947 | Massachusetts General Hospital|United States Department of Defense | Wound Infection|Fractures, Open|Surgical Site Infection | 2022-01-10 | PHASE3 |
| NCT01155999 | Laboratoires Thea | Purulent Bacterial Conjunctivitis | 2008-12 | PHASE3 |
| NCT02657473 | Medical Center Alkmaar | Non-CF Bronchiectasis | 2016-08-13 | PHASE2|PHASE3 |
| NCT02035488 | University Medical Center Groningen | Bronchiectasis | 2013-10 | PHASE1|PHASE2 |
| NCT02528123 | London Vision Clinic | Myopia|Refractive Errors | 2016-04 | NA |
| NCT02102152 | Rabin Medical Center | Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa | 2014-04 | NA |
| NCT01740947 | H. Jaap Bonjer, PhD|Dutch Digestive Diseases Foundation | Colorectal Cancer | 2013-01 | PHASE4 |
| NCT00388505 | Novartis Pharmaceuticals | Cystic Fibrosis | 2006-02 | PHASE3 |
| NCT03715322 | Guangzhou Institute of Respiratory Disease | Bronchiectasis Adult|Pseudomonas Infections | 2018-10-26 | PHASE3 |
| NCT05353101 | Second Affiliated Hospital of Nanchang University | Vernal Keratoconjunctivitis|Cyclosporine 0.05% Eye Drops | 2020-07-01 | PHASE1 |
| NCT00153634 | Seattle Children´s Hospital|Cystic Fibrosis Foundation | Cystic Fibrosis|Chronic Bronchitis | 2004-03 | NA |
| NCT03705962 | University of Virginia | Fractures, Open | 2015-07 | PHASE3 |
| NCT03928522 | Washington University School of Medicine | Total Knee Replacement | 2019-01-28 | PHASE4 |
| NCT06404541 | Kasr El Aini Hospital | Ocular Surface Disease|Dry Eye Syndromes | 2024-01-10 | PHASE4 |
| NCT00004829 | FDA Office of Orphan Products Development | Cystic Fibrosis|Bacterial Infection | 1995-06 | PHASE3 |
| NCT01315678 | Insmed Incorporated | Pseudomonas Aeruginosa Infection | 2012-02-29 | PHASE3 |
| NCT03721328 | Osteal Therapeutics, Inc. | Prosthetic Joint Infection | 2018-10-26 | PHASE2 |
| NCT00992355 | Veroia General Hospital | Cataract | 2009-01 | NA |
| NCT00695435 | Alcon Research | Dry Eye | 2008-06 | PHASE1 |
| NCT02489955 | The Leeds Teaching Hospitals NHS Trust | Cystic Fibrosis | 2015-02 | NA |
| NCT03739528 | NTC srl | Cataract | 2018-09-03 | PHASE3 |
| NCT00885365 | Chiesi Farmaceutici S.p.A. | Cystic Fibrosis | 2009-04 | PHASE3 |
| NCT01028027 | Bausch & Lomb Incorporated | Conjunctivitis|Keratitis|Blepharitis | 2009-10 | PHASE3 |
| NCT01938417 | University of Lausanne Hospitals | Orthopedic Operations | 2006-10 | |
| NCT00774072 | University of Jena | Cystic Fibrosis|Pseudomonas Aeruginosa | 2008-10 | PHASE2 |
| NCT00918957 | Novartis Pharmaceuticals | Cystic Fibrosis | 2009-06 | PHASE3 |
| NCT04297631 | Washington University School of Medicine | Antibotics in Cementless Knees | 2020-02-14 | PHASE4 |
| NCT01079559 | University of Western Ontario, Canada | Infection|Osteoarthritis of the Knee | | PHASE3 |
| NCT00532961 | Bausch & Lomb Incorporated | Inflammation | 2005-02 | PHASE4 |
| NCT00391976 | Novartis | Cystic Fibrosis | 2003-11 | PHASE3 |
| NCT02478710 | Wright State University | Pneumonia, Ventilator-Associated | 2015-06 | PHASE4 |
| NCT01111383 | Chiesi Farmaceutici S.p.A. | Cystic Fibrosis | 2009-09 | PHASE3 |
| NCT01337219 | Erempharma|University of Lyon|Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)|Clininfo S.A.|Hospices Civils de Lyon | Cystic Fibrosis | 2011-04 | PHASE1|PHASE2 |
| NCT03673956 | Mayo Clinic | Chronic Rhinosinusitis (Diagnosis) | 2018-09-26 | PHASE1|PHASE2 |
| NCT00757237 | Gilead Sciences|Chiltern International Inc.|ClinPhone, Inc.|Covance | Cystic Fibrosis | 2008-08 | PHASE3 |
| NCT00420836 | Novartis | Cystic Fibrosis | 2006-04 | PHASE1 |
| NCT02918409 | National Jewish Health | Cystic Fibrosis | 2016-08-26 | PHASE4 |
| NCT00982930 | Novartis Pharmaceuticals | Pseudomonas Aeruginosa|Cystic Fibrosis | 2009-08-12 | PHASE3 |
| NCT02497365 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Bacterial Keratitis | 2015-09 | NA |
| NCT02440828 | Erasmus Medical Center|Chiesi Farmaceutici S.p.A. | Ventilator Associated Pneumonia (VAP) | 2015-03 | PHASE4 |
| NCT00576251 | Alcon Research | Ocular Inflammation Associated With Blepharaconjunctivitis | 2007-10 | PHASE3 |
| NCT01460836 | Novartis Pharmaceuticals | Cystic Fibrosis | 2010-04 | |
| NCT05169229 | University Hospital, Linkoeping|Region ?sterg?tland|The Swedish Research Council | Arthroplasty, Replacement, Hip|Osteoarthritis, Hip|Antibiotic Resistant Infection|Prosthetic Joint Infection | 2022-04-01 | PHASE2|PHASE3 |
| NCT01559753 | Centre Hospitalier Universitaire de Besancon|French Society for Intensive Care|SmithKline Beecham|GlaxoSmithKline | Pneumonia Ventilator Associated | 1998-01 | PHASE4 |
| NCT00362895 | Alcon Research | Cataract | 2006-04 | PHASE3 |
| NCT01677403 | Shandong University | Bronchiectasis | 2012-08 | PHASE4 |
| NCT01103401 | Veroia General Hospital | Cataract | 2009-10 | NA |
| NCT02015663 | Novartis Pharmaceuticals | Cystic Fibrosis | 2014-01 | PHASE4 |
| NCT00198523 | Bausch & Lomb Incorporated | Eye Infections|Postoperative Complications | 2005-07 | PHASE3 |
| NCT02958514 | Peking University Third Hospital | Dry Eye Syndrome | 2016-11 | NA |
| NCT00634192 | Novartis | Pseudomonas Infections | 2008-02 | PHASE3 |
| NCT00447577 | Bausch & Lomb Incorporated | Blepharokeratoconjunctivitis | 2007-01 | PHASE4 |
| NCT03485456 | University Medical Center Groningen | Cystic Fibrosis | 2019-05-29 | PHASE1|PHASE2 |
| NCT03308253 | McMaster University | Surgical Site Infection | 2018-07-16 | PHASE4 |
| NCT01230593 | McMaster University|Icahn School of Medicine at Mount Sinai|Edward-Elmhurst Health System | Chalazion Unspecified Eye, Unspecified Eyelid|Chalazion Left Eye, Unspecified Eyelid|Chalazion Right Eye, Unspecified Eyelid|Chalazion Both Eyes | 2010-11 | NA |
| NCT04872400 | University of Colorado, Denver|Denver Health and Hospital Authority | Fractures, Open|Wounds and Injuries--Infections|Anti-Bacterial Agents|Fractures, Bone|Extremity Fracture Lower|Extremity Fractures Upper | 2021-06-14 | PHASE4 |
| NCT01608555 | University of Milan|Chiesi Farmaceutici S.p.A. | Cystic Fibrosis | 2012-01 | PHASE4 |
| NCT00125346 | Novartis | Cystic Fibrosis | 2005-09 | PHASE3 |
| NCT06093191 | Jin-Fu Xu | Bronchiectasis Adult|Pseudomonas Aeruginosa Infection | 2023-10-18 | PHASE4 |
| NCT07332936 | Umm Al-Qura University | Symptomatic Irreversible Pulpitis|Postoperative Endodontic Pain Following Emergency Root Canal Treatment | 2023-07-01 | NA |
| NCT00006280 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR) | Cystic Fibrosis | 2000-02 | PHASE2 |
| NCT05849090 | University of Utah | Infections | 2023-03-27 | EARLY_PHASE1 |
| NCT00257790 | Oslo University Hospital|The National Institute of Health, Oslo|Ullevaal University Hospital|Sorlandet Hospital HF|Sykehuset Buskerud|Sentralsjukehuset i Rogaland|Sykehuset Innlandet HF|Sentralsjukehuset i Hedemark|The Hospital of Vestfold|Sykehuset Asker og Baerum | Neutropenia|Fever|Cancer | 2001-09 | PHASE4 |
| NCT03341741 | University Hospital Tuebingen | Cystic Fibrosis With Pulmonary Manifestations | 2014-03-11 | PHASE3 |
| NCT02269969 | Sandra Walker | Burns|Infection | 2015-03 | PHASE1|PHASE2 |
| NCT01207245 | University of Nottingham | Cystic Fibrosis | 2011-05 | PHASE4 |
| NCT06106789 | Qianfoshan Hospital | Bronchiectasis|Cystic Fibrosis|Lung Infection | 2023-04-01 | |
| NCT01044719 | Imperial College London | Cystic Fibrosis | 2010-01 | PHASE4 |
| NCT04662632 | Osteal Therapeutics, Inc. | Prosthetic Joint Infection | 2021-11-01 | PHASE2 |
| NCT02677701 | Seattle Children´s Hospital|National Heart, Lung, and Blood Institute (NHLBI)|Cystic Fibrosis Foundation|CF Therapeutics Development Network Coordinating Center | Cystic Fibrosis | 2016-10-21 | PHASE4 |
| NCT02207426 | Pharmaero ApS | Healthy | 2014-07 | PHASE1 |
| NCT05313828 | Sohag University | Corneal Ulcer | 2022-03-18 | |
| NCT00399945 | Novartis | Cystic Fibrosis | 2006-05 | PHASE1 |
| NCT01953367 | Pari Pharma GmbH | Cystic Fibrosis | 2013-09 | PHASE1 |
| NCT00050401 | Pfizer | Pneumonia | 2002-07 | PHASE3 |
| NCT04560179 | Erik Allen Jensen|University of Florida | Bronchopulmonary Dysplasia | 2022-03-22 | PHASE1 |
| NCT05361941 | Elute, Inc. | Periprosthetic Joint Infections | 2023-08-31 | NA |
| NCT00705159 | Bausch & Lomb Incorporated | Conjunctivitis | 2008-06 | PHASE4 |
| NCT00834171 | Allergan | Ocular Hypertension | 2009-01 | |
| NCT02717871 | University Hospital, Geneva | Keratitis; Infectious Disease (Manifestation) | 2016-03 | PHASE3 |
| NCT01570192 | University of Florida | Bacterial Pneumonia | 2010-09 | PHASE2 |
| NCT00105469 | Merck Sharp & Dohme LLC | Bacterial Conjunctivitis | 2004-07 | PHASE3 |
| NCT02526004 | University College Cork|Queen´s University, Belfast|University of Paris 5 - Rene Descartes|University of Dundee|University of Washington|University Hospital Heidelberg|Teagasc|Clininfo S.A.|GABO:mi|Papworth Hospital NHS Foundation Trust|KU Leuven|Assistance Publique - H?pitaux de Paris|European Union | Cystic Fibrosis | 2013-10-01 | NA |
| NCT00823238 | University of North Carolina, Chapel Hill|Cystic Fibrosis Foundation | Cystic Fibrosis | 2004-07 | PHASE1 |
| NCT02054156 | Bonnie Ramsey|National Heart, Lung, and Blood Institute (NHLBI) | Cystic Fibrosis | 2014-06 | PHASE3 |
| NCT06016088 | Respirion Pharmaceuticals Pty Ltd | Cystic Fibrosis Lung|Respiratory Infections, Recurrent, Chronic|Pseudomonas Aeruginosa | 2024-04-01 | PHASE1|PHASE2 |
| NCT03904836 | Maisonneuve-Rosemont Hospital | Renal Dialysis|Renal Failure, Chronic | 2019-01-31 | PHASE1 |
| NCT02888730 | Virginie ESCABASSE|Henri Mondor University Hospital | Cystic Fibrosis|Rhinosinusitis|Lung Diseases | 2017-02-16 | PHASE3 |
| NCT01844778 | Novartis Pharmaceuticals | Cystic Fibrosis | 2013-08 | PHASE4 |
| NCT02873806 | Glaukos Corporation | Open-angle Glaucoma | 2013-03 | PHASE4 |